2010 – 92nd Annual Meeting

[tabs style=”default”] [tab title=”Sunday, May 2″]




  • Gamma Knife Perfexion at MD Anderson: Initial Experience and Illustrative Cases: Eric Chang, MD, Director CNS Stereotactic RT Program Associate Professor of Radiation Oncology.
  • Gamma Knife Perfexion Introduction and Northwestern Experience: John A. Kalapurakal, MD, Professor, Radiation Oncology Director, Radiosurgery Program Northwestern University Medical School Chicago, IL.
  • The FDG-PET Response of Lymph Nodes To Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Does Not Correlate with Pathologic Response: T. Kuan Yu
  • The Role of Adjuvant Therapy in Early Stage Breast Cancer Patients with a Strong Family History: Sabin B. Motwani, MD.
  • Population-based Analysis of Occult Primary Breast Cancer with Axillary Nodal Metastasis: Gary V. Walker M.P.H.
  • Evaluation of Adjuvant Radiation Therapy in the Management of Male Breast Cancer: A Surveillance, Epidemiology, and End Results Analysis: Usama Mahmood MD.
  • Ductal Carcinoma in situ (DCIS) Treated with Wide Excision (>1cm Margins) & Accelerated Partial Breast Irradiation (APBI): Sharad Goyal.
  • A prospective study evaluating tumor bed boost with intra-operative electron irradiation (IOERT) in breast conserving treatment for T1/T2 N0 breast cancer: William Wong, MD
  • Phase III Study Comparing Prone Accelerated Whole Breast IMRT with a Daily vs. Weekly Tumor Bed Boost: S.C. Lymberis.

SCIENTIFIC SESSION #2: CNS Cancer/Pediatric Cancer

  • A mesenchymal expression classifier predicts survival of patients with infiltrating gliomas and correlates with radiation and oncogenic gene signatures: Erik P. Sulman, MD, PH.D.
  • Glioblastoma Stem Cells Mimic Molecular Subtypes of Tumors Associated with Differential Response to Radiation and Temozolomide: Howard Colman.
  • Adverse Events after Gamma Knife Radiosurgery for Parafalcine Compared to Supratentorial Convexity Meningiomas: Philip Schaner Ph.D., MD
  • Marginal Recurrence after Stereotactic Body Radiotherapy for Spinal Metastases Requiring Salvage Radiotherapy: Shlomo A. Koyfman, MD
  • Spinal Re-irradiation Using Stereotactic Body Radiotherapy: Amit K. Garg, MD
  • Infant Brain Tumors: Andrew Bishop, MS
  • Is Height Impairment Present in Children with Acute Lympoblastic Leukemia after 12 to 12.6 GY Cranial Irradiation? Arnold C. Paulino.
  • An Analysis of the Safety and Efficacy of TID Hyperfractionated Total Body Irradiation as Compared to a BID Regimen in Conditioning for Bone Marrow Transplantation: Shapiro RH, Chang AL

PANEL: Technology and Outcomes

  • TECHNOLOGY AND OUTCOMES ROBOTIC PROSTATECTOMY: John W. Davis, MD, Assistant Professor, Urology Director, Urology Prostate Program and Ultrasound Service The University of Texas M. D. Anderson Cancer Center.
  • Emerging Technology Committee (ETC) Activities and Initiatives: Jeff Michalski, MD, MBA, FACR Co-Chair, ASTRO ETC-MSC Professor and Vice-Chair Department of Radiation Oncology Mallinckrodt Institute of Radiology Washington University.
  • Technology Assessment and Coverage of New Medical Technologies in Oncology: Wade M. Aubry, MD
[/tab] [tab title=”Monday, May 3″]

SELF- ASSESSMENT MODULE (SAM): SMALL CELL LUNG CANCER – Kenneth E. Rosenzweig, MD; Memorial Sloan Kettering Cancer Center

KEYNOTE LECTURE: MDACC-RTOG Alliance in Customizing Head & Neck Cancer Therapy – K. Kian Ang, MD, PhD; MD Anderson Cancer Center


  • A Predictive Model of Human Papilloma Virus (HPV) Positivity in Head and Neck Cancer Patients: Alan T. Monroe, MD
  • Post-Radiation Threshold Tumor Volume Predicts Outcome in Head-and-Neck Cancer James D. Murphy, MD
  • CT-Based Tumor-Volume Could Be the Best Prognosticator for Local Control and Organ Preservation of Larynx Cancer Patients After Definitive Conformal Accelerated Radiation Therapy: Krzysztof Skladowski, MD, PhD
  • Enhanced Radiation-Induced DNA Damage and Cell Death With the Use of an Orally Bioavailable PARP1 Inhibitor Olaparib (AZD2281) in BRCA1/BRCA2 Wild-Type Head and Neck Squamous Cell Carcinoma Cell Lines: David Raben, MD
  • Treatment of Carcinomas of the Nasal Vestibule With Interstitial Irradiation: Jack Phan, MD, PhD
  • Stereotactic Radiotherapy in Stage I Non Small Cell Lung Cancer: Ben J. Slotman, MD, PhD
  • Predictors of Chest Wall Toxicity Following Stereotactic Body Radiotherapy for Early Stage Non-Small Cell Lung Cancer: Robert Mutter – TRAVEL GRANT WINNER
  • Clinical Outcomes of Patients With Malignant Lung Lesions Treated With Stereotactic Body Radiation Therapy: Hua Ren, MD, PhD
  • A Polymorphism in the Promoter of the TGF-Beta Gene is Associated With Radiation Sensitivity Using an Objective Radiologic Endpoint: Chris R. Kelsey, MD


  • The Benefit of Consolidative Radiation Therapy in Patients With Diffuse Large B-Cell Lymphoma Treated With RCHOP Chemotherapy: Jack Phan, MD, PhD – TRAVEL GRANT WINNER
  • A Novel Method for Transcutaneous Gene Therapy Silences Smad3: Gene Expression Profiles of Radiation Fibrosis Investigated: Judy W. Lee, MD
  • Dose-Dependent Radioprotection by Antagonists of Growth Hormone Releasing Hormone Given Before Whole Body Radiation is Dependent on Organ-Specific Upregulation of Target Genes: May Abdel-Wahab, MD
  • Somatostatin Receptor Subtype 2-Targeted Copper Radiopharmaceuticals for Cancer Imaging and Therapy: Albert J. Chang, MD, PhD – TRAVEL GRANT WINNER
  • Comparison of Gross Tumor Volumes as Measured by Micro FDG-PET/CT to Pathologic Tumor Volumes in a Mouse Model: Jennifer Hoefert, BA
  • Morbid Obesity and Heterotopic Ossification Waleed: F. Mourad, MD, MSc – TRAVEL GRANT WINNER
  • Male Cancer Survivor Use of Internet-Based Survivorship Care Plans: Christine Hill-Kayser, MD


[/tab] [tab title=”Tuesday, May 4″]

JANEWAY LECTURE: Melanoma as an Example of Evidence-Based Medicine

Charles M. Balch, MD, Johns Hopkins Medical Institute


  • Mediator of DNA Damage Checkpoint Protein 1 (MDC1) Expression as a Prognostic Marker for Nodal Recurrence in Early-Stage Breast Cancer Patients Treated With Breast-Conserving Surgery and Radiation Therapy: Akshar N. Patel, BS
  • MammoSite Brachytherapy Versus Whole Breast Irradiation:
    Analysis of Patient Outcomes Stratified by the ASTRO Consensus Statement Groups for Accelerated Partial Breast Irradiation: A. Jason Zauls, MD
  • Down-Regulation of MicroRNA 106b Is Involved in p21-Mediated Cell Cycle Arrest in Response to Radiation in Prostate Cancer Cells: Baoqing Li, MD, PhD
  • What is the Role of Radiation Therapy in Stage I and II Hodgkin’s Disease?
    Matthew Koshy, MD
  • Postoperative Radiotherapy Use and Patterns of Care Analysis for Node Positive or Parametria Positive Cervical Cancer: Amol J. Ghia, MD
  • Prognostic Utility of Squamous Cell Carcinoma Antigen in Carcinoma of the Cervix: Correlation with Pre- and Post-Treatment FDG-PET: Jeffrey R. Olsen, MD

Proton Therapy for Lung/Prostate:

  • Should Randomized Studies be Required for Adopting New Technologies? James D. Cox, MD, Anderson Cancer Center
  • Randomized Trials of Proton Therapy are needed in Lung and Prostate Cancer:
    Joel E. Tepper, MD; University of North Carolina School of Medicine
  • Economic Considerations for Proton Therapy: James D. Cox, MD, Anderson Cancer Center


  • Biomarker Expression Can Identify Biologically Distinct Categories of Invasive Breast Cancer:
  • Association Between Locoregional Outcomes and Biologic Subtype in Locally Advanced Breast Cancer (LABC): Cristiane Takita, MD
  • COX-2 Correlates With Risk of Ipsilateral Breast Tumor Recurrence Early-Stage Breast Cancer Patients Treated With Breast-Conserving Surgery and Radiation Therapy:
    Atif J. Khan, MD, MS
  • Estrogen Receptor (ER) Positive, Progesterone Receptor (PR) Negative or ER-PR+ Breast Cancer Predicts Locoregional Recurrence But Not Distant Metastases Compared to ER+PR+ Disease in Patients With Node-Negative Disease and Tumors One Centimeter or Less:
    Jeffrey M. Albert, MD
  • Local-Regional Outcomes in Triple-Negative Breast Cancer Patients Who Receive Breast Conservation Therapy: Stephen H. Settle, MD, PhD
  • GM-CSF and IFN-Gamma Up-Regulation With Stereotactic Body Radiation Therapy for Oligometastatic Breast Cancer Correlates With Improved Overall Survival:
    Su K. Metcalfe, MD, MPH


  • Impact of ioMRI on Extent of Resection in Surgery for Brain Tumors: Jeffrey Weinberg, MD MD Anderson Cancer Center
  • Update on current trends in the management of spinal tumors: Eric Chang, MD MD Anderson Cancer Center
  • Radiosurgery for Benign Spinal Tumors and Functional Applications: Iris C. Gibbs, MD Stanford School of Medicine
[/tab] [tab title=”Wednesday, May 5″]



  • Molecular Imaging Guided Radiation Oncology:
    Richard Wahl, MD, Johns Hopkins University School of Medicine


  • Different Planning Software Could Lead to Different Dosimetric Results: Matched-Pair Analysis of Two Types of Software for Interstitial Permanent Brachytherapy for Prostate Cancer
    Hiromichi Ishiyama, MD
  • Single Institution Experience with Cesium-131 Brachytherapy for Prostate Cancer Patients
    Aaron W. Pederson, MD
  • Shorter Treatment Time Reduces Intrafraction Prostate Motion: Jay Shelton, MD
  • Pelvic Nodal Dose Escalation With Simultaneous Integrated Hypofractionated Prostate IMRT for High Risk Prostate Cancer: Jarrod B. Adkison, MD
  • Analysis of Pathologic Extent of Disease for Clinically Localized Prostate Cancer After Radical Prostatectomy and Subsequent Use of Adjuvant Radiation in a National Cohort
    David Schreiber, MD – TRAVEL GRANT WINNER
  • Dynamic Contrast Enhanced (DCE) MRI Post-Prostatectomy for a Rising PSA: Implications for Radiotherapy: Raj S. Rajpara, BS
  • Multi-Modal Real-Time Three-Dimensional Ultrasound-Based Imaging for Detection of Prostate Cancer in Men: Hans T. Chung, MD, FRCPC


  • Factors Influencing Survival in Patients Undergoing a Palliative Bypass Procedure for Pancreatic Adenocarcinoma: Phillip J. Gray, MD, The Johns Hopkins Experience
  • Multiinstitutional Phase II Trial of Induction Cetuximab Gemcitabine and Oxaliplatin, Followed By Radiotherapy With Concurrent Capecitabine, and Cetuximab, for Locally Advanced Pancreatic Adenocarcinoma (LAPC): Christopher H. Crane, MD
  • Outcome Analysis of Intensity Modulated Radiation Therapy and Concurrent Chemoradiation Therapy for Anal Carcinoma in NCI-Designated Integrated Cancer Center Network
    Sarahgene G. DeFoe, MD
  • Prospective Trial of Stereotactic Body Radiation Therapy for Colorectal Oligometastases
    Su K. Metcalfe, MD, MPH
  • FDG-PET-Based Prognostic Nomogram for Locally Advanced Cervical Cancer
    Elizabeth A. Kidd, MD – TRAVEL GRANT WINNER
  • Chemoradiation Response-Suppressing Potential of Ribonucleotide Reductase p53R2 in Cervical Cancers: Charles Kunos, MD, PhD
  • Contemporary Analysis of Pelvic and Para-Aortic Metastasis in Endometrial Cancer Using the SEER Database: Evangelia Katsoulakis, MD


[/tab] [/tabs]